Our Science
March 30, 2026
Alnylam Named One of Fast Company's Most Innovative Companies for 2026
RNAi therapeutics pioneer has been recognized by Fast Company as one of the most innovative companies for the 3rd time and ranks #3 in the "Medicines and Therapeutics" category.
Read More ›
December 17, 2025
Alnylam Announces Major Expansion of U.S. Pharmaceutical Manufacturing Facility
$250 million investment will add new capacity and siRNA enzymatic ligation capabilities to Alnylam's Norton, Massachusetts site
Read More ›
December 8, 2025
The Future of Medicine is in Our Genes
Additional human genetics data partnerships are helping scientists identify new drug targets, improving the chances of developing effective medicines
Read More ›
September 30, 2025
How Alnylam’s Manufacturing Investments Bring RNAi Therapeutics to More Patients, Faster
Translating our pioneering work in RNAi not only requires innovation in the lab - it requires innovation in how we make our medicines.
Read More ›
August 26, 2025
RNAi Therapeutics: 5 Things You Should Know about this Innovative Class of Medicines
What is RNAi and what do RNAi therapeutics do? Here are 5 things you should know!
Read More ›
February 21, 2025
A New Therapeutic Approach Seeks to Silence Devastating Neurological Diseases
Exploring the potential of RNAi therapeutics to tackle brain diseases with few or no treatments
Read More ›
September 26, 2024
Confronting the World’s Leading Killer with a New Therapeutic Approach
For Xicang Guo and Jiaming Zhang, one particular condition remains stubbornly beyond their control – hypertension, also known as high blood pressure.
Read More ›
September 12, 2024
RNAi Therapeutics, from Possibility to Patients
The story of an innovative approach to silencing disease that’s improving lives and changing expectations for medicine.
Read More ›
FOLLOW US
